The reason for the study is to find out if an experimental combination of an oral medication
called Almonertinib when used in combination with chemotherapy is more effective for the
treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are
due to mutations in the Deoxyribonucleic acid (DNA) which, if known, can help physicians
decide the best treatment for patients. One type of mutation can occur in the gene that
produces a protein on the surface of cells called the Epidermal Growth Factor Receptor
(EGFR).
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital